Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.

Cancer letters - 28 Aug 2024

Zhang Hongyan, Zhang Longlong, He Yuna, Jiang Dewei, Sun Jian, Luo Qianmei, Liang Huichun, Wang Tiantian, Li Fubing, Tang Yu, Yang Zimo, Liu Wenjing, Rao Yu, Chen Ceshi

Abstract excerpt

Although anti-HER2 therapy has made significant strides in reducing metastasis and relapse in HER2-positive breast cancer, resistance to agents like trastuzumab, pertuzumab, and lapatinib frequently develops in patients undergoing treatment. Previous studies suggest that the hyperactivation of the PI3K-AKT signaling pathway by PIK3CA/PTEN gene mutations is implicated in HER2 resistance. In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Lapatinib

Share to Mice, Nude

Share to Proteolysis

Share to Thiazoles

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38986734
DOI: 10.1016/j.canlet.2024.217112

Genes

PIK3CA
MB
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.PMID 38986734Read ↗

Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability.Semantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cellsSemantic proximity Read ↗

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current AchievementsSemantic proximity Read ↗

PROTACs as Potential Therapeutic Agents for Cancer Drug ResistanceSemantic proximity Read ↗

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cellsSemantic proximity Read ↗

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathwaySemantic proximity Read ↗

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancerSemantic proximity Read ↗

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.Semantic proximity Read ↗

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Semantic proximity Read ↗

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.